High materiality8/10
Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
Why it may matterVerify against the original reporting
upside_potential_confirmed
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Bernstein reiterates Outperform on ALNY with a target of $376; current price $236.01.
- ALNY: Target $376; Price $236.01; Firm: Bernstein; Analyst: Jeffrey Walch; Rating: Outperform
Key facts
- 01
Target: $376
- 02
Posted price: $236.01
- 03
Analyst firm: Bernstein
- 04
Analyst: Jeffrey Walch
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.